Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2017-02-07 Report Publication Anno…
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Presentation of the fourth quarter and full year 2016 results
Report Publication Announcement Classification · 92% confidence The document explicitly announces the 'Presentation of the fourth quarter and full year 2016 results' scheduled for a specific date and time, including details for both a physical presentation and an audio webcast/conference call. This content is an announcement about an upcoming event where results will be discussed, rather than the full financial report (10-K or IR) or the initial highlights (ER). Since it details the logistics for presenting results, it strongly aligns with the description of a Call Transcript (CT) if it were the transcript itself, or an Investor Presentation (IP) if it were the slides. However, the text itself is purely an invitation and logistical announcement for the presentation/call. Given the options, this is an announcement detailing an event where results will be presented, which often precedes or accompanies an Investor Presentation (IP) or is related to an Earnings Call (CT). Since the document is short (1907 chars) and focuses on *when* and *how* to access the presentation/call, it fits the 'Menu vs Meal' rule if interpreted as an announcement of the presentation materials. However, the core subject is the presentation of results, which is the primary function of an Investor Presentation (IP) or the event leading to a Call Transcript (CT). Given the context of 'Presentation of the results', IP is the most fitting category for the materials being presented, even if this specific text is the invitation. If this were a regulatory filing announcement, RPA would apply, but this is specific to results presentation logistics. I will classify it as Investor Presentation (IP) as it describes the event where the presentation materials will be shared, which is the closest fit for result presentation materials among the specific options, although RPA is a possibility if strictly adhering to the 'announcement' nature.
2017-02-07 English
Photocure Completes Enrollment in US Market expansion study of Blue Light Flexible Cystoscopy (BLFC) with Cysview ®
Regulatory Filings Classification · 95% confidence The document text is a press release dated February 3, 2017, announcing that Photocure ASA has completed enrollment in a Phase 3 study for its BLFC with Cysview product. It details the study's purpose (seeking FDA approval for expanded use), provides context on bladder cancer, and includes company contact information. This format—a formal announcement of a significant operational or clinical milestone via a press release—does not fit the specific financial report categories (10-K, IR, ER, etc.). Since it is a general, time-sensitive corporate announcement that doesn't fit other specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), it falls best under the general Regulatory Filings/Announcements category, RNS, which serves as a broad category for official company news releases.
2017-02-03 English
Photocure ASA: Chairperson Bente-Lill Romøren not candidate for re-election
Board/Management Information Classification · 100% confidence The document explicitly announces that the Chairperson of the Board of Directors, Bente-Lill Romøren, will not seek re-election at the upcoming 2017 Annual General Meeting. This content directly relates to changes in the company's board composition and leadership structure. This fits the definition of Board/Management Information (MANG). The document is short and is an announcement, not a presentation or formal report.
2017-01-23 English
Photocure to present at investor meetings in San Francisco
Investor Presentation Classification · 99% confidence The document is titled '# Photocure ASA' and is dated 'JANUARY 2017'. It contains extensive slides detailing investment highlights, market data (sales figures, growth rates), clinical data regarding Hexvix®/Cysview®, inclusion in national guidelines (AUA/SUO), and future opportunities. The structure, use of bullet points, charts, and forward-looking statements strongly indicate this is a presentation prepared for investors or analysts. This aligns perfectly with the definition of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a short announcement (RPA/RNS) as the document is substantial (38,206 characters).
2017-01-09 English
Photocure to present at investor meetings in San Francisco
Investor Presentation Classification · 95% confidence The document is very short (1193 characters) and announces that management will be presenting at investor meetings in San Francisco in connection with the J.P. Morgan healthcare conference. Crucially, it states, 'Please find the presentation attached.' This indicates the document itself is an announcement about an upcoming presentation/meeting, not the presentation material (IP) or a formal regulatory filing. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement stating a presentation is attached points towards a Report Publication Announcement (RPA) or a general Investor Relations communication. Since the core purpose is announcing participation in investor meetings and attaching related material, 'Investor Presentation' (IP) is a strong candidate if the attachment is the presentation, but the announcement itself fits best under a general Investor Relations/Presentation announcement category. Given the options, this is an announcement related to investor engagement and presentation materials. While 'IP' is for the presentation itself, this is the announcement of the presentation/meeting. 'RPA' is for announcing the publication of reports. Since this is an announcement about investor meetings and attaching a presentation, it is most closely related to Investor Presentation materials being made available. However, given the context of announcing participation in investor meetings and attaching the presentation, it functions as an Investor Presentation announcement. If the attached document is the presentation, 'IP' is appropriate. If we strictly follow the 'MENU VS MEAL' rule for short announcements, it leans towards RPA or RNS. Since the content is explicitly about an investor presentation, and it's short, it's likely an announcement *about* the presentation. Let's re-evaluate: It announces management will present and attaches the presentation. This is a common format for releasing the presentation materials themselves to the public via an announcement. Given the options, 'Investor Presentation' (IP) is the most specific category for the *content* being shared, even if this specific text is the wrapper announcement. If it were purely a regulatory filing announcement, RNS/RPA would apply. Since it's investor-focused material being released, IP is the best fit for the underlying subject matter being made public.
2017-01-09 English
US registry shows that Blue Light Cystoscopy (BLC) with Cysview®/Hexvix® leads to improved detection and classification of bladder cancer
Investor Presentation Classification · 95% confidence The document text consists of a structured presentation abstract detailing a medical study ('REPEAT USE OF BLUE LIGHT CYSTOSCOPY WITH HEXAMINOLEVULINATE FOR PATIENTS WITH UROTHELIAL CELL CARCINOMA'). It includes sections for Purpose, Methods, Results, Conclusion, and a data table. The content is highly specific, academic, and appears to be material presented at a scientific meeting (Poster #3, 17th Annual Meeting of the Society of Urologic Oncology). This format strongly suggests an Investor Presentation (IP) or similar detailed presentation material, rather than a formal regulatory filing (like 10-K, ER, or IR). Given the options, 'Investor Presentation' (IP) is the most appropriate classification for detailed, structured scientific/clinical data presented to an audience, even if the audience is specialized medical professionals rather than purely financial investors, as it represents a deep dive into company/product performance/data.
2016-12-05 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.